Pulmatrix, Inc.
PULMHealthcare|Biotechnology|US
$1.38
-0.02 (-1.43%)
DCF Value
$1.05
Tangible Book / Share
$0.70
Cash / Share
$0.59
Clinical Trials (16)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT02280395 A Phase I/II Double-Blind, Randomized, Controlled Study to Evaluate the Safety and Efficacy of RUT058-60 | Postoperative Wound Infection-deep, Post Operative Wound Infection | P1P2 | Terminated | 9 | RCT, Double-blind | RUT058-60, Sterile saline for irrigation |
| NCT05667662 Study to Evaluate Itraconazole Administered as Inhaled Dry Powder in Adults With Asthma and ABPA | ABPA | P2 | Terminated | 8 | RCT, Double-blind | Itraconazole Powder, Placebo |
| NCT03960606 Study in Adult Asthmatic Patients With Allergic Bronchopulmonary Aspergillosis | Allergic Bronchopulmonary Aspergillosis | P2 | Terminated | 7 | RCT, Double-blind | — |
| NCT05351086 A Study to Assess the Safety, Tolerability, and Pharmacokinetics of PUR3100 in Health Adults | Healthy | P1 | Completed | 26 | RCT, Double-blind | PUR3100, Dihydroergotamine (D.H.E 45) |
| NCT01921712 A Safety, Pharmacokinetic and Pharmacodynamic Study of PUR0200 in COPD Patients | Chronic Obstructive Pulmonary Disease (COPD) | P1 | Completed | 38 | RCT, Double-blind | PUR0200, PUR0200 Placebo, Active comparator |
| NCT03479411 Safety, Tolerability and Pharmacokinetics of PUR1900 (Itraconazole Powder) in Healthy Volunteers and Adults With Asthma | Asthma | P1 | Completed | 58 | RCT, Open-label | Itraconazole Powder, Itraconazole 200 mg |
| NCT01690949 Evaluation of the Effect of PUR118 on Ozone Induced Airway Inflammation in Healthy Normal Volunteers | Chronic Obstructive Pulmonary Disease (COPD) | P1 | Completed | 24 | RCT, Single-blind | PUR118 |
| NCT02671825 A PK Study to Evaluate PUR0200 and a Reference Product in Healthy Subjects | Healthy | P1 | Completed | 42 | RCT, Open-label | PUR0200, Reference Product |
| NCT01543191 A Safety and Tolerability Study OF PUR118 In Subjects With Cystic Fibrosis | Cystic Fibrosis | P1 | Completed | 10 | RCT, Double-blind | PUR118 |
| NCT02198963 21 Day Cumulative Skin Irritation of RUT058-60 | Irritation/Irritant | P1 | Completed | 43 | RCT, Double-blind | Hypochlorous acid solution 106 mg/L, 0.1% (w/v) Sodium Lauryl Sulfate, 0.9% Physiological Saline, USP |
| NCT04759807 A Phase 1b Study of PUR1800 in Patients With COPD | Chronic Obstructive Pulmonary Disease (COPD) | P1 | Completed | 18 | RCT, Double-blind | Placebo Comparator, PUR1800 250 ug, PUR1800 500 ug |
| NCT01333904 Safety, Tolerability, and Pharmacodynamic Effect Study of PUR118 | Chronic Obstructive Pulmonary Disease | P1 | Completed | 90 | RCT, Open-label | PUR118 |
| NCT00989521 Effect of PUR003 on Asthma | Asthma, Lung Diseases | P1 | Completed | 7 | RCT, Double-blind | PUR003, Placebo |
| NCT00947687 Safety and Efficacy Study of Inhaled PUR003 on a Controlled Influenza Virus Challenge in Healthy Adult Subjects | Healthy | P1 | Completed | 24 | RCT, Double-blind | PUR003, Placebo |
| NCT05903612 Allergic Bronchopulmonary Aspergillosis Prescreening Study | Allergic Bronchopulmonary Aspergillosis, Asthma | Withdrawn | — | — | — | |
| NCT01096173 Determination of the in Vitro Effects of Cationic Airway Lining Modulators (CALM) on Chronic Obstructive Pulmonary Disease (COPD) Sputum | Chronic Obstructive Pulmonary Disease | Completed | 10 | — | — |